IN10018 in combination with PLD Clinical Trials

1 actively recruiting trial

Also known as: IN10018 add on to PLD treatment

Pipeline

Phase 1/2: 1

Top Sponsors

InxMed (Shanghai) Co., Ltd.1

Indications

Platinum-resistant Ovarian Cancer1
Cancer1

Other1 trial

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.